RECORDATI (RER1.SG) (RER1 STU) stock market data APIs
€54.3549
0.42(0.8%)
as of June 13, 2025
Try our APIs with
free plan!
RECORDATI (RER1.SG) Financial Data Overview
There is no Profile data available for RER1.SG.
Prev. Close
54.3549
Open
54.7766
High
54.7766
Low
52.7462
52 wk Range
43.7894-58.7576
Market Cap
11 024 M
Dividends (Yield)
0.0252
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RECORDATI (RER1.SG) data using free add-ons & libraries
Get RECORDATI (RER1.SG) Fundamental Data
RECORDATI (RER1.SG) Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RECORDATI (RER1.SG) News
New
3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%
As European markets face heightened volatility due to escalating trade tensions, the pan-European STOXX Europe 600 Index recently ended lower, reflecting investor concerns over global economic growth....
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
Recordati RECORDATI: FDA GRANTS ISTURISA®(OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA® is a cortisol synthesi...
3 European Stocks Estimated To Be Undervalued In March 2025
As European markets navigate a complex landscape of mixed inflation data and economic contractions in major economies like Germany and France, the pan-European STOXX Europe 600 Index has shown resilie...
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
Recordati RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS Consolidat...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
